Changes in primary and secondary hemostasis in patients with CLL treated with venetoclax and ibrutinib
| العنوان: | Changes in primary and secondary hemostasis in patients with CLL treated with venetoclax and ibrutinib |
|---|---|
| المؤلفون: | Rebecka Svanberg, Rogier Mous, Mattias Mattson, Arnon P. Kater, Sabina Kersting, Hoa T. T. Tran, Kazem Nasserinejad, Carsten Utoft Niemann, Sisse R. Ostrowski, Johan A. Dobber, Mark-David Levin |
| المساهمون: | Experimental Immunology, Clinical Haematology, CCA - Cancer Treatment and Quality of Life, Hematology |
| المصدر: | Leukemia & lymphoma, 61(14), 3422-3431. Informa Healthcare Leukemia and Lymphoma, 61(14), 3422-3431. Informa Healthcare |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Oncology, Cancer Research, medicine.medical_specialty, Combination therapy, Chronic lymphocytic leukemia, medicine.medical_treatment, Targeted therapy, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Piperidines, SDG 3 - Good Health and Well-being, ibrutinib, Internal medicine, Humans, Medicine, Adverse effect, Sulfonamides, medicine.diagnostic_test, venetoclax, business.industry, Venetoclax, Adenine, Hematology, Bridged Bicyclo Compounds, Heterocyclic, medicine.disease, bleeding, targeted therapy, Leukemia, Lymphocytic, Chronic, B-Cell, Thromboelastography, chemistry, 030220 oncology & carcinogenesis, Hemostasis, Ibrutinib, hemostasis, business, CLL, 030215 immunology |
| الوصف: | Bleeding is a common adverse event following ibrutinib monotherapy. However, it remains unclear how hemostasis is affected by venetoclax in combination with ibrutinib. Here we investigated hemostasis in patients with chronic lymphocytic leukemia (CLL) at baseline, during ibrutinib monotherapy, and during venetoclax and ibrutinib combination therapy or venetoclax monotherapy. Primary hemostasis, assessed by Multiplate using adenosine diphosphate (ADP), arachidonic acid (AA), and thrombin receptor agonist peptide (TRAP-6), was impaired in all CLL patients at baseline, remained unchanged upon ibrutinib monotherapy, and improved significantly following venetoclax added to ibrutinib or as monotherapy. Secondary hemostasis assessed by thromboelastography (TEG) was normal and unchanged throughout treatment. The frequency of clinical bleeding events was the highest during ibrutinib monotherapy, in line with the demonstrated improved primary hemostasis upon addition of venetoclax, thus pointing toward a treatment option for CLL patients with increased bleeding risk. |
| اللغة: | English |
| تدمد: | 1042-8194 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc0f70b5835d929e019d6156845d5ba8 https://doi.org/10.1080/10428194.2020.1811270 |
| حقوق: | RESTRICTED |
| رقم الأكسشن: | edsair.doi.dedup.....fc0f70b5835d929e019d6156845d5ba8 |
| قاعدة البيانات: | OpenAIRE |
PDF full text from Publisher | تدمد: | 10428194 |
|---|